GH21
Phase 2- Indications
- Non-small cell lung cancer
Company intelligence / Profile preview
Genhouse Bio
Suzhou, Jiangsu, China
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Genhouse Bio has advanced several first-in-class or best-in-class small molecule oncology programs into the clinic. Notably, their SHP2 inhibitor GH21 has been outlicensed ex-China to HUYABIO International and entered coordinated global clinical testing. Their pipeline includes a KRAS inhibitor (GH35) in Phase I studies in China, a KIF18A inhibitor (GH2616) recently entering first-in-human trials for solid tumors, and preclinical work on novel Hippo pathway modulators such as YAP1/TEAD inhibitors. The company emphasizes targeting "undruggable" cancer drivers using innovative chemistry platforms.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesAllosteric inhibitors (e.g., SHP2 inhibitor)KIF18A inhibitorYAP1/TEAD interaction inhibitors
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
HUYABIO International (out-license of ex-China rights to SHP2 inhibitor GH21/HBI‑2376)
Beyond the preview
Go deeper on Genhouse Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genhouse Bio.